Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 2-3/2014

01-12-2014 | PATHOGENESIS AND THERAPY IN AUTOIMMUNE DISEASES

Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients

Authors: Mohan S. Maddur, Magalie Rabin, Pushpa Hegde, Francis Bolgert, Moneger Guy, Jean-Michel Vallat, Laurent Magy, Jagadeesh Bayry, Srini V. Kaveri

Published in: Immunologic Research | Issue 2-3/2014

Login to get access

Abstract

Guillain–Barré syndrome (GBS) is an acute, autoimmune inflammatory disorder of peripheral nervous system characterized by a severe functional motor weakness. Treatment with intravenous immunoglobulin (IVIg) is one of the approved and preferred therapeutic strategies for GBS. However, the mechanisms underlying the therapeutic benefit with IVIg in GBS are not completely understood. In the present study, we observed that GBS patients have increased frequencies of Th1 and Th17 cells, but reduced number of Foxp3+ regulatory T cells (Treg cells) with defective functions. We show that IVIg treatment in GBS patients results in a marked reduction in the frequency of Th1 and Th17 cells with a concomitant expansion of Treg cells. Importantly, IVIg-expanded Treg cells exhibited an increased T cell suppressive function. Together our results demonstrate that therapeutic benefit of IVIg in GBS patients implicates the reciprocal regulation of Th1/Th17 and Treg cells.
Literature
1.
Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747–55.CrossRefPubMed
2.
Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev. 2012;11(11):792–4.CrossRefPubMed
3.
Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev. 2008;7(6):435–9.CrossRefPubMed
4.
Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011;7(6):349–59.CrossRefPubMed
5.
Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367–75.CrossRefPubMed
6.
Nussinovitch U, Shoenfeld Y. Intravenous immunoglobulin—indications and mechanisms in cardiovascular diseases. Autoimmun Rev. 2008;7(6):445–52.CrossRefPubMed
7.
Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367(21):2015–25.CrossRefPubMed
8.
Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med. 2008;359(3):307–9.CrossRefPubMed
9.
Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011;164(Suppl 2):2–5.PubMedCentralCrossRefPubMed
10.
Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011;36(1):9–15.CrossRefPubMed
11.
Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA. 2004;101(39):14210–5.PubMedCentralCrossRefPubMed
12.
Bayry J, Lacroix-Desmazes S, Hermine O, Oksenhendler E, Kazatchkine MD, Kaveri SV. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med. 2005;118(12):1439–40.CrossRefPubMed
13.
Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol. 2007;3(5):262–72.CrossRefPubMed
14.
Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7(6):440–4.CrossRefPubMed
15.
Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27(3):233–45.CrossRefPubMed
16.
Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29(12):608–15.CrossRefPubMed
17.
Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176–89.CrossRefPubMed
18.
Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127(2):315–23.CrossRefPubMed
19.
Svetlicky N, Ortega-Hernandez OD, Mouthon L, Guillevin L, Thiesen HJ, Altman A, et al. The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade. J Clin Immunol. 2013;33(Suppl 1):S27–32.CrossRefPubMed
20.
21.
van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain–Barre syndrome. Lancet Neurol. 2008;7(10):939–50.CrossRefPubMed
22.
Eldar AH, Chapman J. Guillain–Barre syndrome and other immune mediated neuropathies: diagnosis and classification. Autoimmun Rev. 2014;13(4–5):525–30.CrossRefPubMed
23.
Li S, Jin T, Zhang HL, Yu H, Meng F, Concha Quezada H et al. Circulating Th17, Th22, and Th1 Cells are elevated in the Guillain–Barre syndrome and downregulated by IVIg treatments. Mediat Inflamm. 2014. doi:10.​1155/​2014/​740947.
24.
Li XL, Dou YC, Liu Y, Shi CW, Cao LL, Zhang XQ, et al. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cell Immunol. 2011;271(2):455–61.CrossRefPubMed
25.
Zhang HL, Zheng XY, Zhu J. Th1/Th2/Th17/Treg cytokines in Guillain–Barre syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev. 2013;24(5):443–53.CrossRefPubMed
26.
Li S, Yu M, Li H, Zhang H, Jiang Y. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain–Barre syndrome. Mediat Inflamm. 2012;2012:260473.
27.
28.
Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485–517.CrossRefPubMed
29.
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and Type 17 helper T cells. N Engl J Med. 2009;361(9):888–98.CrossRefPubMed
30.
Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012;181(1):8–18.CrossRefPubMed
31.
Roark CL, Huang Y, Jin N, Aydintug MK, Casper T, Sun D, et al. A canonical Vγ4 Vδ4+ γδ T cell population with distinct stimulation requirements which promotes the Th17 response. Immunol Res. 2013;55(1–3):217–30.PubMedCentralCrossRefPubMed
32.
33.
Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res. 2014;58(1):61–9.CrossRefPubMed
34.
Su Z, Sun Y, Zhu H, Liu Y, Lin X, Shen H, et al. Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis. Immunol Res. 2014;58(1):118–24.CrossRefPubMed
35.
36.
Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol. 2013;13(6):461–7.CrossRefPubMed
37.
Wehrens EJ, Prakken BJ, van Wijk F. T cells out of control—impaired immune regulation in the inflamed joint. Nat Rev Rheumatol. 2013;9(1):34–42.CrossRefPubMed
38.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87.CrossRefPubMed
39.
Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11(1):7–13.CrossRefPubMed
40.
Andre S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol. 2009;174(5):1575–87.PubMedCentralCrossRefPubMed
41.
Kobezda T, Ghassemi-Nejad S, Mikecz K, Glant TT, Szekanecz Z. Of mice and men: how animal models advance our understanding of T-cell function in RA. Nat Rev Rheumatol. 2014;10(3):160–70.PubMedCentralCrossRefPubMed
42.
Pellerin L, Jenks JA, Begin P, Bacchetta R, Nadeau KC. Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res. 2014;58(2–3):358–68.PubMedCentralCrossRefPubMed
43.
Pedroza-Pacheco I, Madrigal A, Saudemont A. Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol. 2013;10(3):222–9.PubMedCentralCrossRefPubMed
44.
Lin SJ, Lu CH, Yan DC, Lee PT, Hsiao HS, Kuo ML. Expansion of regulatory T cells from umbilical cord blood and adult peripheral blood CD4(+)CD25(+) T cells. Immunol Res. 2014;60(1):105–11.CrossRefPubMed
45.
Harness J, McCombe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain–Barre syndrome patients compared to controls. J Clin Neurosci. 2008;15(9):1031–5.CrossRefPubMed
46.
Chi LJ, Wang HB, Zhang Y, Wang WZ. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain–Barre syndrome. J Neuroimmunol. 2007;192(1–2):206–14.CrossRefPubMed
47.
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain–Barre syndrome. Cochrane Database Syst Rev. 2012;7:CD002063.PubMed
48.
van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain–Barre syndrome. J Clin Immunol. 2010;30(Suppl 1):S74–8.CrossRefPubMed
49.
El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain–Barre syndrome: a randomized study. Crit Care. 2011;15(4):R164.PubMedCentralCrossRefPubMed
50.
Harel M, Shoenfeld Y. Intravenous immunoglobulin and Guillain–Barre syndrome. Clin Rev Allergy Immunol. 2005;29(3):281–7.CrossRefPubMed
51.
Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol. 2010;30(Suppl 1):S4–8.CrossRefPubMed
52.
53.
De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood. 2008;112(8):3303–11.PubMedCentralCrossRefPubMed
54.
Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4+ CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111(2):715–22.CrossRefPubMed
55.
Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007;179(8):5571–5.CrossRefPubMed
56.
Massoud AH, Guay J, Shalaby KH, Bjur E, Ablona A, Chan D, et al. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. J Allergy Clin Immunol. 2012;129(6):1656–65 e3.CrossRefPubMed
57.
Massoud AH, Yona M, Xue D, Chouiali F, Alturaihi H, Ablona A, et al. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol. 2014;133(3):853–63 e5.CrossRefPubMed
58.
Olivito B, Taddio A, Simonini G, Massai C, Ciullini S, Gambineri E, et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol. 2010;28(1 Suppl 57):93–7.PubMed
59.
Tha-In T, Metselaar HJ, Bushell AR, Kwekkeboom J, Wood KJ. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+ Foxp3+ T cells. Transplantation. 2010;89(12):1446–55.CrossRefPubMed
60.
Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol. 2012;39(5):1019–25.CrossRefPubMed
61.
Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood. 2013;122(8):1419–27.CrossRefPubMed
62.
Tjon AS, Tha-In T, Metselaar HJ, van Gent R, van der Laan LJ, Groothuismink ZM, et al. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol. 2013;173(2):259–67.PubMedCentralCrossRefPubMed
63.
Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol. 2011;127(3):823–30 e1-7.CrossRefPubMed
64.
Maddur MS, Kaveri SV, Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev. 2011;10(12):809–10.CrossRefPubMed
65.
Maddur MS, Sharma M, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. J Clin Immunol. 2013;33(Suppl 1):S62–6.CrossRefPubMed
66.
Othy S, Hegde P, Topcu S, Sharma M, Maddur MS, Lacroix-Desmazes S, et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol. 2013;190(9):4535–41.CrossRefPubMed
67.
Othy S, Topcu S, Saha C, Kothapalli P, Lacroix-Desmazes S, Kasermann F, et al. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur J Immunol. 2014;44(7):2059–63.CrossRefPubMed
68.
Liu G, Yang K, Burns S, Shrestha S, Chi H. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol. 2010;11(11):1047–56.PubMedCentralCrossRefPubMed
69.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain–Barre syndrome. Ann Neurol. 1990;27(Suppl):S21–4.CrossRefPubMed
70.
Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2002;72(5):596–601.PubMedCentralCrossRefPubMed
71.
Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973–6.PubMedCentralCrossRefPubMed
72.
Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38(3):414–23.CrossRefPubMed
73.
Bayry J, Siberil S, Triebel F, Tough DF, Kaveri SV. Rescuing CD4+ CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today. 2007;12(13–14):548–52.CrossRefPubMed
74.
Maddur MS, Trinath J, Rabin M, Vallat JM, Magy L, Balaji KN et al. Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with an increased prostaglandin E2 in the circulation. Cell Mol Immunol (in press).
75.
76.
Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol. 2010;162(1):131–7.PubMedCentralCrossRefPubMed
77.
Kim DJ, Lee SK, Kim JY, Na BJ, Hur SE, Lee M, et al. Intravenous immunoglobulin g modulates peripheral blood Th17 and Foxp3(+) regulatory T cells in pregnant women with recurrent pregnancy loss. Am J Reprod Immunol. 2014;71(5):441–50.CrossRefPubMed
78.
Lee SY, Jung YO, Ryu JG, Kang CM, Kim EK, Son HJ, et al. Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of th17 and treg cells in an interleukin-10-dependent manner. Arthritis Rheumatol. 2014;66(7):1768–78.CrossRefPubMed
79.
Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101(2):758–65.CrossRefPubMed
80.
Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48(12):3497–502.CrossRefPubMed
81.
Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Hermine O, Tough DF, Kaveri SV. Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol. 2005;175(1):15–20.CrossRefPubMed
82.
Aubin E, Lemieux R, Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood. 2010;115(9):1727–34.CrossRefPubMed
83.
Othy S, Bruneval P, Topcu S, Dugail I, Delers F, Lacroix-Desmazes S, et al. Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: role of lipid accumulation. J Autoimmun. 2012;39(3):168–72.CrossRefPubMed
84.
Wiedeman AE, Santer DM, Yan W, Miescher S, Kasermann F, Elkon KB. Contrasting mechanisms of interferon-alpha inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists. Arthritis Rheum. 2013;65(10):2713–23.PubMed
85.
86.
87.
Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, et al. Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood. 2012;120(6):1237–45.CrossRefPubMed
88.
Trinath J, Hegde P, Balaji KN, Kaveri SV, Bayry J. Intravenous immunoglobulin-mediated regulation of Notch ligands on human dendritic cells. J Allergy Clin Immunol. 2013;131(4):1255–7 7 e1.CrossRefPubMed
89.
Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev. 2013;12(3):436–43.CrossRefPubMed
90.
Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475(7354):110–3.PubMedCentralCrossRefPubMed
91.
Bayry J, Bansal K, Kazatchkine MD, Kaveri SV. DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci USA. 2009;106(9):E24.PubMedCentralCrossRefPubMed
92.
Leontyev D, Katsman Y, Branch DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP. Blood. 2012;119(22):5261–4.CrossRefPubMed
93.
Sharma M, Schoindre Y, Hegde P, Saha C, Maddur MS, Stephen-Victor E, et al. Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Sci Rep. 2014;4:5672. doi:10.​1038/​srep05672.PubMed
94.
Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol. 2014;192(11):5031–8.PubMedCentralCrossRefPubMed
95.
Bayry J, Lacroix-Desmazes S, Dasgupta S, Kazatchkine MD, Kaveri SV. Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants? Nat Rev Immunol. 2008;8(1). doi:10.​1038/​nri2138-c1.
96.
Maddur MS, Hegde P, Sharma M, Kaveri SV, Bayry J. B cells are resistant to immunomodulation by ‘IVIg-educated’ dendritic cells. Autoimmun Rev. 2011;11(2):154–6.CrossRefPubMed
97.
Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood. 2010;116(10):1698–704.CrossRefPubMed
98.
Seite JF, Goutsmedt C, Youinou P, Pers JO, Hillion S. Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. J Allergy Clin Immunol. 2014;133(1):181–8 e1-9.CrossRefPubMed
99.
Moriguchi K, Miyamoto K, Takada K, Kusunoki S. Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy. J Neuroimmunol. 2011;238(1–2):107–9.CrossRefPubMed
100.
Casulli S, Topcu S, Fattoum L, von Gunten S, Simon HU, Teillaud JL, et al. A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One. 2011;6(10):e26469.PubMedCentralCrossRefPubMed
101.
Semple JW, Kim M, Hou J, McVey M, Lee YJ, Tabuchi A, et al. Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production. PLoS One. 2012;7(2):e31357.PubMedCentralCrossRefPubMed
102.
von Gunten S, Shoenfeld Y, Blank M, Branch DR, Vassilev T, Kasermann F, et al. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat Rev Immunol. 2014;14(5):349.CrossRef
Metadata
Title
Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients
Authors
Mohan S. Maddur
Magalie Rabin
Pushpa Hegde
Francis Bolgert
Moneger Guy
Jean-Michel Vallat
Laurent Magy
Jagadeesh Bayry
Srini V. Kaveri
Publication date
01-12-2014
Publisher
Springer US
Published in
Immunologic Research / Issue 2-3/2014
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-014-8580-6

Other articles of this Issue 2-3/2014

Immunologic Research 2-3/2014 Go to the issue

FRONTIERS IN AUTOIMMUNITY

Risk factors of systemic lupus erythematosus flares during pregnancy

FRONTIERS IN AUTOIMMUNITY

Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination

PATHOGENESIS AND THERAPY IN AUTOIMMUNE DISEASES

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): clues and pitfalls in the pediatric background

PATHOGENESIS AND THERAPY IN AUTOIMMUNE DISEASES

Chronic fatigue syndrome and fibromyalgia following immunization with the hepatitis B vaccine: another angle of the ‘autoimmune (auto-inflammatory) syndrome induced by adjuvants’ (ASIA)

FRONTIERS IN AUTOIMMUNITY

Autoimmune thyroid disease and rheumatoid arthritis: relationship and the role of genetics

PATHOGENESIS AND THERAPY IN AUTOIMMUNE DISEASES

No male predominance in offspring of women with rheumatoid arthritis or systemic lupus erythematosus